Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in the management of endocrine-sensitive HR+/HER2− metastatic breast cancer (mBC) with a focus on treatment options following first-line endocrine therapy plus a CDK4/6 inhibitor. In this educational program, these experts discuss the role of mutational testing to guide therapy selection and the efficacy and safety of next-generation targeted therapies, including oral SERDs and PI3K, AKT, and mTOR inhibitors. The program also addresses best practices for managing adverse effects and uses a case-based format to provide practical insights to improve patient care.

This educational activity is an archive of the live presentation held on May 7, 2026.

Target Audience

This educational program is primarily directed toward community-based medical oncologists, surgical oncologists, advanced practice providers, nurses, and other health care providers involved in the treatment of metastatic breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Apply guideline-concordant approaches for molecular testing in patients with HR+/HER2− mBC across the disease continuum
• Evaluate recent real-world evidence providing practical insights into the use of targeted treatment strategies for HR+/HER2− mBC
• Integrate clinical trial and real-world data alongside patient- and disease-specific characteristics into personalized treatment decisions for patients with HR+/HER2− mBC
• Develop evidence-based strategies for monitoring and mitigating adverse effects associated with targeted therapies for HR+/HER2− mBC

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.25 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Stemline Therapeutics, Inc.